Rosiglitazone: a European regulatory perspective
Tóm tắt
Từ khóa
Tài liệu tham khảo
European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. Press release, 23 September 2010. Available from www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/09/WC500096996.pdf
EMEA (2000) European Public Assessment Report (EPAR) initial marketing authorisation documents–Avandia–Scientific Discussion. Available from www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000268/WC500029103.pdf [containing amendments up to 2004]
Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471
Drazen JM, Morrissey S, Curfman GD (2007) Rosiglitazone—continued uncertainty about safety. N Engl J Med 357:63–64
Montori VM, Gandhi GY, Guyatt GH (2007) Patient-important outcomes in diabetes—time for consensus. Lancet 370:1104–1106
Psaty BM, Furberg CD (2007) The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med 357:67–69
Rosen CJ (2007) The rosiglitazone story—lessons from an FDA Advisory Committee meeting. N Engl J Med 357:844–846
Home PD, Jones NP, Pocock SJ et al (2007) Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med 24:626–634
Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125–2135
Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289
Nathan DM, Buse JB, Davidson MB et al (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17–30
Graham DJ, Ouellet-Hellstrom R, MaCurdy TE et al (2010) Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304:411–418
Nissen SE, Wolski K (2010) Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 170:1191–1201
McEvoy B. 2010. Pioglitazone and rosiglitazone cardiovascular safety meta-analyses. FDA Advisory Committee, 13–14 July 2010. Available from www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM224739.pdf
Wertz DA, Chang CL, Sarawate CA, Willey VJ, Cziraky MJ, Bohn RL (2010) Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population. Circ Cardiovasc Qual Outcomes 3:538–545
EMA (2010) THIN database study on rosiglitazone use. Available from www.encepp.eu/encepp/viewResource.htm?id=1592 , accessed 7 October 2010
EMA (2008) Concept paper on the need for revision of the note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus. Available from www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003182.pdf
EMA (2010) Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus—draft. Available from www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/02/WC500073570.pdf
US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (2008) Guidance for Industry. Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention—draft. Available from www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071624.pdf
UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853
US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (2008) Guidance for Industry. Diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available from www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf